FDA Has "Substantial Interest" In Reviewing Off-Label Uses, Judge Rules
Executive Summary
FDA has a "substantial interest" in adding off-label uses of previously approved drugs to product labeling, D.C. federal court Judge Royce Lamberth ruled July 30 in the first amendment case brought against FDA by the Washington Legal Foundation.